Current Research Studies
An 18-month, open-label, single-arm safety extension study of an age-and bodyweight adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria
FIONA OLE
What is the goal of the study?
This is an Open Label Extension of the the Finerenone study, which we are currently a site enrolling patients, SCH IRB STUDY00003735. Finerenone is currently being studied in pediatric patients with CKD and severely increased proteinuria despite optimized treatment with an ACEI or ARB in the 6-month double-blind, placebo controlled FIONA study (19920). The primary study aim is to provide data on the long-term safety of finerenone in the treatment of pediatric and young adult patients with CKD. In addition, further study goals are to collect data on the long-term efficacy and to offer access to finerenone to all participants previously treated in the FIONA study (19920).
Who can participate in the study?
Please contact the study team listed below to learn more.